Global Blood Therapeutics Inc (NASDAQ:GBT) Expected to Post Quarterly Sales of $1.05 Million

Equities analysts expect Global Blood Therapeutics Inc (NASDAQ:GBT) to post $1.05 million in sales for the current quarter, Zacks reports. Four analysts have provided estimates for Global Blood Therapeutics’ earnings, with the lowest sales estimate coming in at $200,000.00 and the highest estimate coming in at $2.00 million. The company is scheduled to report its next quarterly earnings report on Wednesday, February 26th.

According to Zacks, analysts expect that Global Blood Therapeutics will report full-year sales of $940,000.00 for the current year, with estimates ranging from $200,000.00 to $2.00 million. For the next financial year, analysts forecast that the company will report sales of $41.48 million, with estimates ranging from $21.10 million to $68.99 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that follow Global Blood Therapeutics.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same quarter last year, the business earned ($0.83) earnings per share.

A number of equities research analysts have commented on GBT shares. Nomura raised their target price on Global Blood Therapeutics from $109.00 to $112.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $98.00 price target (down from $110.00) on shares of Global Blood Therapeutics in a research note on Monday, November 25th. ValuEngine cut shares of Global Blood Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. William Blair reiterated a “buy” rating on shares of Global Blood Therapeutics in a report on Tuesday, October 8th. Finally, SunTrust Banks raised their price objective on shares of Global Blood Therapeutics to $110.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $91.44.

Shares of GBT stock opened at $76.15 on Friday. The business’s fifty day moving average price is $54.14 and its 200 day moving average price is $53.59. The firm has a market capitalization of $4.01 billion, a PE ratio of -22.33 and a beta of 1.70. The company has a debt-to-equity ratio of 0.04, a current ratio of 14.95 and a quick ratio of 14.95. Global Blood Therapeutics has a 1-year low of $34.92 and a 1-year high of $77.95.

In related news, insider De Dominicis Robert 490,012 shares of the stock in a transaction dated Tuesday, October 22nd. Also, insider Lesley Ann Calhoun sold 2,765 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $54.36, for a total transaction of $150,305.40. Following the transaction, the insider now directly owns 887 shares of the company’s stock, valued at $48,217.32. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,616 shares of company stock valued at $2,096,540. Company insiders own 4.30% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Metropolitan Life Insurance Co NY grew its holdings in Global Blood Therapeutics by 6.5% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 17,963 shares of the company’s stock valued at $872,000 after buying an additional 1,090 shares during the last quarter. Man Group plc purchased a new stake in shares of Global Blood Therapeutics in the third quarter valued at $2,671,000. Point72 Asset Management L.P. purchased a new stake in shares of Global Blood Therapeutics in the third quarter valued at $34,343,000. California State Teachers Retirement System boosted its stake in shares of Global Blood Therapeutics by 7.7% during the third quarter. California State Teachers Retirement System now owns 90,269 shares of the company’s stock valued at $4,380,000 after acquiring an additional 6,446 shares during the last quarter. Finally, Pictet Asset Management Ltd. boosted its stake in shares of Global Blood Therapeutics by 22.9% during the third quarter. Pictet Asset Management Ltd. now owns 539,510 shares of the company’s stock valued at $26,177,000 after acquiring an additional 100,653 shares during the last quarter. Hedge funds and other institutional investors own 98.78% of the company’s stock.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

See Also: Consumer Price Index (CPI)

Get a free copy of the Zacks research report on Global Blood Therapeutics (GBT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.